DEFI Gestion

Europe, Vaud, Switzerland, Lausanne

Description

DEFI Gestion SA has close to CHF 200 million in assets under management, for institutional as well as individual clients.

Investor Profile

DEFI Gestion has backed more than 4 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 2 exits across its portfolio.

Investment Focus Highlights

Concentrates on Post Ipo Equity, Series B, Series A rounds (top funding stages).
Majority of deals are located in Switzerland.
Strong thematic focus on Biotechnology, Health Care, Medical Device.

Stage Focus

Post Ipo Equity (50%)
Series B (25%)
Series A (25%)

Country Focus

Switzerland (100%)

Industry Focus

Biotechnology
Health Care
Medical Device
Biopharma
Medical
Therapeutics

FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does DEFI Gestion frequently co-invest with?

Gimv

Europe, Antwerpen, Belgium, Antwerpen

Co-Investments: 1

Innovation Capital

Innovation Capital

Europe, Ile-de-France, France, Paris

Co-Investments: 1

Sectoral Asset Management

Sectoral Asset Management

North America, Quebec, Canada, Montréal

Co-Investments: 1

VI Partners

Europe, Schwyz, Switzerland, Altendorf

Co-Investments: 3

Ysios Capital

Europe, Pais Vasco, Spain, San Sebastian

Co-Investments: 1

Andera Partners

Andera Partners

Europe, Ile-de-France, France, Paris

Co-Investments: 1

Neomed Management

Neomed Management

Europe, Oslo, Norway, Oslo

Co-Investments: 3

VINCI CAPITAL

Europe, Vaud, Switzerland, Lausanne

Co-Investments: 2

CDC Enterprises

Europe, Ile-de-France, France, Paris

Co-Investments: 1

Reference Capital SA

Reference Capital SA

Europe, Geneve, Switzerland, Genève

Co-Investments: 2

What are some of recent deals done by DEFI Gestion?

Lausanne, Vaud, Switzerland

NanoPowers was a medical device company that used their artificial muscle technology to improve muscle function in human beings.

BiotechnologyHealth CareMedical Device

Series AJun 1, 2010

Amount Raised: $4,500,000

Geneva, Geneve, Switzerland

Endosense is a medical tech company focused on improving the reproducibility of catheter ablation for the treatment of cardiac arrhythmias.

BiotechnologyHealth CareMedical DeviceTherapeutics

Series BOct 27, 2009

Amount Raised: $36,000,000

Kuros Biosciences

Schlieren, Zurich, Switzerland

Kuros Biosurgery develops biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine.

BiopharmaBiotechnologyHealth CareMedical

Post Ipo EquityOct 1, 2005

Amount Raised: $4,330,754

Kuros Biosciences

Schlieren, Zurich, Switzerland

Kuros Biosurgery develops biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine.

BiopharmaBiotechnologyHealth CareMedical

Post Ipo EquityJan 1, 2005

Amount Raised: $5,433,454